AIPT - Precision Therapeutics, Inc.


Weak GrowthEarnings/Profit is Negative


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -14.72%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) Growth is -87.04%
Net Margin is -2084.45%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 8.65
Debt Ratio is 0.1
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Precision Therapeutics, Inc. (AIPT) -
Precision Therapeutics, Inc. engages in the manufacture and distribution of healthcare products, and provision of related services. The company offers STREAMWAY System, which is an automated system for the collection and disposal of infectious fluids from surgical and other medical procedures. It operates through the Medical Device and Consumable Products segments. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.
Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - Carl Schwartz
Employees - 24

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.